| Similar Articles |
|---|
 |
Bio-IT World
October 2005 |
New Products Minimizing Variation, Maximizing Results... Speeding Up with GEArray Express... Sizing Down Sample Storage... Software's New Dimension... High-Precision Mouse Genome CGH Microarray...   |
Bio-IT World
December 15, 2004
Kevin Davies |
First Trilogy Machine Installed at Mount Sinai A landmark installation for U.S. Genomics' Single Molecule Analyzer. |
The Motley Fool
March 17, 2011
Brian Orelli |
Eat or Be Eaten? Perhaps Both. Oft-rumored takeout target Human Genome Sciences goes shopping. |
Bio-IT World
August 13, 2002
Malorye Branca |
The Proteomics Odyssey Efforts to map the constellation of protein interactions in humans gather momentum as companies vie to provide tools to capitalize on the potential of proteomics. But can proteomics prevail where some feel genomics has failed? |
The Motley Fool
March 29, 2006
Stephen D. Simpson |
Novartis Bulks Up Its Pipeline The Swiss drug giant once again pays up to add trial candidates to its portfolio. Investors, take note. |
The Motley Fool
January 20, 2005
Stephen D. Simpson |
Novartis Posts a Swiss Miss The Swiss drug giant has a strong pipeline, but moderate growth and high valuation suggest little room for error. |
Bio-IT World
June 15, 2003
Kevin Davies |
The Overly Bold and the Beautiful For many (who really ought to know better), the temptation to fetishize DNA is all but irresistible. |
The Motley Fool
March 26, 2004
Charly Travers |
Human Genome Getting on Track What a novel concept for a drug company to focus on commercializing drugs. |
The Motley Fool
October 23, 2006
Brian Lawler |
No Slowing Novartis The Swiss pharmaceutical company shows strength in nearly all its divisions. Novartis looks like a good investment for risk-adverse investors searching for a large-cap pharma stock. |
Bio-IT World
January 21, 2005 |
Defining 'Integrative Genomics' Five experts from academia and industry discuss the burgeoning field of integrative genomics. |
Bio-IT World
August 13, 2003
Malorye Branca |
Targeting Tumors Next-generation cancer drugs will take aim with unprecedented certainty, but making them requires a new discovery and development paradigm. |
IEEE Spectrum
February 2010
Mark Anderson |
Genome as Commodity In a few years, millions will have purchased their own genome. The cultural ramifications of a $100 genome are as wide and deep as those of any other recent innovation, including search engines and cellphones. |
The Motley Fool
October 30, 2009
Brian Orelli |
Earnings? Yawn. Trial Data? Moving! For Human Genome Sciences investors, the anticipation is frightening. |
The Motley Fool
April 14, 2011
Brian Orelli |
Human Genome Sciences Will Be Profitable, Eventually With its first drug on the market -- nearly 20 years after the company was founded -- Human Genome Sciences should start to show meaningful revenue this year. |
The Motley Fool
March 31, 2008
Brian Lawler |
SGX Down for the Count? The pharmaceutical's lead drug fares poorly in clinical testing. |
Bio-IT World
February 18, 2004 |
Strategic Insights High-throughput gene-expression analysis tools are moving rapidly into clinical labs, setting the stage for dramatic improvements in drug development. |
The Motley Fool
May 29, 2008
Brian Lawler |
Human Genome's Jam-Packed Pipeline This drugmaker has plentiful candidates heading for phase 3 testing. |
Fast Company
September 2000
John Ellis |
The Secret of Life The mapping of the human genome, says Craig Venter, will change science, research, medicine, politics, health insurance, and the way biology looks at the last 3 billion years of evolution. And that's just the beginning. |
Bio-IT World
January 13, 2003
John Dodge |
Talent Fuels Drug Pipeline in Swiss Time The functional genomics group has emerged as a critical link in the drug discovery chain at Novartis Pharmaceuticals Corp. While it employs a multidisciplinary approach to drug discovery, the four-year-old group's goals could not be simpler: Find novel drug targets. |
| Knowledge@Wharton |
From Skin Creams to Life Insurance to Medical Care, Biosciences Are the New Frontier of Business Opportunity Research in the biological sciences holds the potential for breakthroughs that could transform the world. But scientific advances also can be baffling and more than a little intimidating, especially for business people... |
The Motley Fool
December 19, 2006
Brian Gorman |
Novartis Cuts in Line at the Drugstore Consolidation in pharmacy benefits management may leave Novartis most resistant to pricing pressure. Investors, take note. |
Bio-IT World
October 2005
Dennis A. Gilbert |
The DNA Sequencing Race: From Sprint to Marathon To create faster, cheaper, and better solutions for DNA analysis, we must remain committed to improving both current and new sequencing technologies. Research that just a short while ago might have been considered too complex, too expensive, or just inconceivable is now well within our grasp. |
Science News
December 15, 2007 |
Science Safari: My DNA Project A new website to help people become comfortable with genome issues and learn how to take advantage of the discoveries made possible by the Human Genome Project. |
Bio-IT World
August 18, 2004
Kevin Davies |
Bio IT World President's Award: Francis Collins The director of the National Human Genome Research Institute (NHGRI) spoke of collaboration and computation during his acceptance speech. |
The Motley Fool
March 16, 2005
Cliff Malings |
Nice of You to Notice Novartis The Street finally pays attention to a longtime pharma winner on news of a major generic-drug acquisition. |
Bio-IT World
April 15, 2003
Malorye Branca |
Beyond the Blueprint How will the wealth of data emanating from the human genome and allied technologies impact research on health and disease? |
The Motley Fool
February 28, 2008
Brian Lawler |
Too Much Hope in Human Genome Shares Human Genome announces its guidance for 2008. Investors, take note. |
Fast Company
November 2009
David H. Freedman |
The Gene Bubble: Why We Still Aren't Disease-Free When the human genome was first sequenced nearly a decade ago, the world lit up with talk about how new gene-specific drugs would help us cheat death. Well, the verdict is in: Keep eating those greens. |
The Motley Fool
June 7, 2006
Stephen D. Simpson |
Novartis Can't Say No The Swiss drug giant signs more deals to boost its pipeline. Investors, here is a strong company in a weak sector that's still somewhat undervalued -- not exactly the worst story of the week. |
Bio-IT World
August 13, 2003
Michael Greeley |
Two Cents on the '$1,000 Genome' Are venture capitalists still looking for 'the killer app'? Funding the next big idea won't be so easy. Affordable, individualized genome sequencing holds great promise, but making the claims sound too grandiose can be dangerous. |
BusinessWeek
May 9, 2005 |
A Genome Pioneer Looks Forward Dr. Francis Collins discusses the end of the Human Genome Project and says an "outpouring of discoveries" is coming soon. |
The Motley Fool
February 27, 2009
Brian Orelli |
Waiting to Inhale Human Genome Sciences is guiding for revenue of $250 million this year compared to less than $50 million last year, thanks to its sale of anthrax emergency treatment ABthrax to the government. |
The Motley Fool
October 26, 2011
Brian Orelli |
Down 20%: Benylsta Not Ramping Fast Enough Sales of Human Genome Sciences' new lupus drug Benylsta continues to grow -- just not fast enough to keep investors interest. |
